Novo A Buys Praxis Precision Medicines Inc, Aligos Therapeutics Inc, Eargo Inc, Sells Vanguard Total Stock Market ETF, Medtronic PLC, Catalent Inc

Investment company Novo A (Current Portfolio) buys Praxis Precision Medicines Inc, Aligos Therapeutics Inc, Eargo Inc, Galecto Inc, Freeline Therapeutics Holdings PLC, sells Vanguard Total Stock Market ETF, Medtronic PLC, Catalent Inc, SI-BONE Inc, Vaxcyte Inc during the 3-months ended 2020Q4, according to the most recent filings of the investment company, Novo A. As of 2020Q4, Novo A owns 43 stocks with a total value of $2.2 billion. These are the details of the buys and sells.

• New Purchases: PRAX, ALGS, EAR, GLTO, LUNG, FSTX,
• Added Positions: FRLN, VRNA, MIST, PTGX, CNST,
• Reduced Positions: VTI, CTLT, AAPL, PCVX, CABO, FOLD, SPNE, HRMY, GRTX, SPRO, BPMC, SILK, INSP, CRVS, NARI, XENT, BHVN,
• Sold Out: MDT, SIBN, CVAC, AKBA, ETTX,

• FRLN 30-Year Financial Data
• The intrinsic value of FRLN
• Peter Lynch Chart of FRLN

For the details of Novo A's stock buys and sells, go to https://www.gurufocus.com/guru/novo+a/current-portfolio/portfolio

1. Vanguard Total Stock Market ETF (VTI) - 1,933,900 shares, 17.11% of the total portfolio. Shares reduced by 37.01%
2. Nkarta Inc (NKTX) - 2,793,864 shares, 7.81% of the total portfolio.
3. Inogen Inc (INGN) - 3,549,320 shares, 7.21% of the total portfolio.
4. Apple Inc (AAPL) - 1,037,404 shares, 6.26% of the total portfolio. Shares reduced by 17.15%
5. Praxis Precision Medicines Inc (PRAX) - 2,442,080 shares, 6.11% of the total portfolio. New Position

Novo A initiated holding in Praxis Precision Medicines Inc. The purchase prices were between $27.25 and $55.82, with an estimated average price of $38.91. The stock is now traded at around $35.560000. The impact to a portfolio due to this purchase was 6.11%. The holding were 2,442,080 shares as of 2020-12-31.

Novo A initiated holding in Aligos Therapeutics Inc. The purchase prices were between $13.2 and $32.74, with an estimated average price of $19.48. The stock is now traded at around $24.140000. The impact to a portfolio due to this purchase was 3.29%. The holding were 2,614,563 shares as of 2020-12-31.

Novo A initiated holding in Eargo Inc. The purchase prices were between $33.49 and $57.94, with an estimated average price of $42.12. The stock is now traded at around $55.750000. The impact to a portfolio due to this purchase was 1.5%. The holding were 737,071 shares as of 2020-12-31.

Novo A initiated holding in Galecto Inc. The purchase prices were between $12.51 and $16.84, with an estimated average price of $14.88. The stock is now traded at around $10.120000. The impact to a portfolio due to this purchase was 1.42%. The holding were 2,497,791 shares as of 2020-12-31.

Novo A initiated holding in Pulmonx Corp. The purchase prices were between $41.35 and $69.02, with an estimated average price of $49.13. The stock is now traded at around $57.700000. The impact to a portfolio due to this purchase was 0.59%. The holding were 187,047 shares as of 2020-12-31.

Novo A initiated holding in F-star Therapeutics Inc. The purchase prices were between $4.06 and $10.39, with an estimated average price of $8.53. The stock is now traded at around $8.680000. The impact to a portfolio due to this purchase was 0.02%. The holding were 34,819 shares as of 2020-12-31.

Novo A added to a holding in Freeline Therapeutics Holdings PLC by 255.07%. The purchase prices were between $14.94 and $18.3, with an estimated average price of $16.78. The stock is now traded at around $14.560000. The impact to a portfolio due to this purchase was 1.41%. The holding were 2,361,229 shares as of 2020-12-31.

Novo A added to a holding in Verona Pharma PLC by 44.87%. The purchase prices were between $5.51 and $8.11, with an estimated average price of $6.76. The stock is now traded at around $8.880000. The impact to a portfolio due to this purchase was 0.26%. The holding were 2,608,755 shares as of 2020-12-31.

Novo A added to a holding in Milestone Pharmaceuticals Inc by 21.63%. The purchase prices were between $5.57 and $7.66, with an estimated average price of $6.69. The stock is now traded at around $6.590000. The impact to a portfolio due to this purchase was 0.14%. The holding were 2,530,585 shares as of 2020-12-31.

Novo A sold out a holding in Medtronic PLC. The sale prices were between $100.57 and $117.14, with an estimated average price of $110.21.

Novo A sold out a holding in SI-BONE Inc. The sale prices were between $20.44 and $30.88, with an estimated average price of $24.36.

Novo A sold out a holding in CureVac NV. The sale prices were between $46.76 and $136.27, with an estimated average price of $77.02.

Novo A sold out a holding in Akebia Therapeutics Inc. The sale prices were between $2.22 and $3.78, with an estimated average price of $2.93.

Novo A sold out a holding in Entasis Therapeutics Holdings Inc. The sale prices were between $1.61 and $2.85, with an estimated average price of $1.96.

Novo A reduced to a holding in Vanguard Total Stock Market ETF by 37.01%. The sale prices were between $166.99 and $194.64, with an estimated average price of $183.18. The stock is now traded at around $200.360000. The impact to a portfolio due to this sale was -9.61%. Novo A still held 1,933,900 shares as of 2020-12-31.

Novo A reduced to a holding in Catalent Inc by 38.66%. The sale prices were between $85.88 and $105.36, with an estimated average price of $97.08. The stock is now traded at around $108.370000. The impact to a portfolio due to this sale was -2.67%. Novo A still held 997,349 shares as of 2020-12-31.

Novo A reduced to a holding in Vaxcyte Inc by 35.98%. The sale prices were between $26.57 and $51.74, with an estimated average price of $37.01. The stock is now traded at around $25.830000. The impact to a portfolio due to this sale was -0.58%. Novo A still held 416,937 shares as of 2020-12-31.

Novo A reduced to a holding in Amicus Therapeutics Inc by 27.38%. The sale prices were between $13.47 and $24.89, with an estimated average price of $20.55. The stock is now traded at around $10.660000. The impact to a portfolio due to this sale was -0.45%. Novo A still held 1,684,795 shares as of 2020-12-31.

Novo A reduced to a holding in SeaSpine Holdings Corp by 20.17%. The sale prices were between $12.76 and $18.33, with an estimated average price of $15.24. The stock is now traded at around $18.170000. The impact to a portfolio due to this sale was -0.24%. Novo A still held 1,339,085 shares as of 2020-12-31.

Novo A reduced to a holding in Spero Therapeutics Inc by 38.06%. The sale prices were between $12.06 and $22.07, with an estimated average price of $15.65. The stock is now traded at around $17.320000. The impact to a portfolio due to this sale was -0.2%. Novo A still held 576,702 shares as of 2020-12-31.